News & Updates
Filter by Specialty:
En bloc resection significantly reduces NMIBC recurrence at 1 year
A multicentre, randomized, phase III trial conducted by researchers from the Chinese University of Hong Kong (CUHK) demonstrated a significant reduction in 1-year recurrence of non–muscle-invasive bladder cancer (NMIBC) with the use of en bloc vs standard resection (SR).
En bloc resection significantly reduces NMIBC recurrence at 1 year
25 Jun 2024
Longest ever PFS in advanced NSCLC CROWNs lorlatinib’s 5-year data
After 5 years of follow-up, median progression-free survival (PFS) has still not been reached in patients with advanced non-small-cell lung cancer (NSCLC) treated with lorlatinib in the phase III CROWN study, corresponding to the longest PFS ever reported with any single-agent molecular targeted treatment in advanced NSCLC and across all metastatic solid tumours.
Longest ever PFS in advanced NSCLC CROWNs lorlatinib’s 5-year data
25 Jun 2024
Drugs.com detects more drug–drug interactions in breast cancer patients
A recent study has found more potential drug‒drug interactions in breast cancer patients receiving doxorubicin and cyclophosphamide regimen in the Drugs.com database than in the Lexicomp and Micromedex databases.
Drugs.com detects more drug–drug interactions in breast cancer patients
24 Jun 2024
Statin use may reduce mortality in early breast cancer
The addition of statins to standard adjuvant breast cancer treatment, particularly in combination with chemotherapy, appears to improve patient survival, suggests a study presented at ESMO Breast Cancer 2024.
Statin use may reduce mortality in early breast cancer
19 Jun 2024
PANTHER 10-year data support tailored dose-dense adjuvant chemo for high-risk early breast cancer
Long-term data from the phase III PANTHER trial demonstrate improved breast cancer recurrence-free survival (BCRFS) with tailored dose-dense adjuvant chemotherapy as opposed to standard adjuvant chemo in individuals with high-risk early breast cancer.